Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Long-Term Deferred Tax (2020 - 2025)

Cytek Biosciences' Long-Term Deferred Tax history spans 6 years, with the latest figure at $38.4 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 24.74% year-over-year to $38.4 million; the TTM value through Sep 2025 reached $38.4 million, up 24.74%, while the annual FY2024 figure was $33.4 million, 9.47% up from the prior year.
  • Long-Term Deferred Tax reached $38.4 million in Q3 2025 per CTKB's latest filing, up from $35.8 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $38.4 million in Q3 2025 to a low of $7.4 million in Q2 2021.
  • Average Long-Term Deferred Tax over 5 years is $23.3 million, with a median of $25.2 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: soared 125.74% in 2023, then rose 3.06% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $9.2 million in 2021, then soared by 123.03% to $20.5 million in 2022, then surged by 49.02% to $30.5 million in 2023, then increased by 9.47% to $33.4 million in 2024, then grew by 15.04% to $38.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Long-Term Deferred Tax are $38.4 million (Q3 2025), $35.8 million (Q2 2025), and $33.7 million (Q1 2025).